MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Washtien, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Washtien, W. L.

Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells

WL Washtien

Thymidylate synthetase levels in five human gastrointestinal tumor cell lines (two colon, two colorectal, one stomach) were determined. Titration of the enzyme in cell cytosol using the active-site titrant, 5-fluoro-2'-deoxyuridine-5'-monophosphate, demonstrated a 20-fold variation in the level of this enzyme among the tumor lines. Titrations performed in the presence or absence of added methylenetetrahydrofolate gave the same values for enzyme content. The cytotoxicity of 5- fluorodeoxyuridine to these cell lines (expressed as EC50 values) varied from 0.44 nM for SW 403 cells to 16 nM for HuTu 80 cells, and in all cases was reversed by the addition of thymidine. The concentration of 5-fluorodeoxyuridine required for cytotoxicity correlated directly (r = 0.98) with the level of thymidylate synthetase in the particular cell line. An inverse correlation (r = -0.95) was observed between the concentration of methotrexate producing cytotoxicity in these cell lines and their thymidylate synthetase levels. The cells were found to contain similar levels of dihydrofolate reductase and to possess normal transport capability for methotrexate.

Volume 21, Issue 3, pp. 723-728, 05/01/1982
Copyright © 1982 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
L. Li, S. H. Berger, and M. D. Wyatt
Involvement of base excision repair in response to therapy targeted at thymidylate synthase
Mol. Cancer Ther., June 1, 2004; 3(6): 747 - 753.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. M. Landis and L. A. Loeb
Random Sequence Mutagenesis and Resistance to 5-Fluorouridine in Human Thymidylate Synthases
J. Biol. Chem., October 2, 1998; 273(40): 25809 - 25817.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1982 by the American Society for Pharmacology and Experimental Therapeutics